A patient is taking benzodiazepines for anxiety.
Which adverse effect should the nurse warn about?

Choice A rationale

While following the medication schedule strictly is a crucial part of medication administration, it is not the absolute priority. Administering a medication at the wrong time could potentially harm the patient if other checks are not performed first, highlighting that the core safety checks are the foremost priority.

Choice B rationale

Ensuring the patient takes the medication correctly is an important step in the process, but it follows the initial and more critical steps of verifying the medication and dose. If the incorrect drug is prepared or the wrong dose is calculated, the act of the patient taking it correctly becomes irrelevant and potentially dangerous.

Choice C rationale

The nurse's highest priority is to confirm the right medication, dose, route, and patient, as this practice, known as the "five rights," is the cornerstone of patient safety. This step minimizes the risk of administering the wrong drug, the wrong dose, or to the wrong patient, which could lead to severe adverse outcomes.

Choice D rationale

Documentation is a vital part of the medication administration process for legal and continuity of care purposes, but it must be done after the medication has been administered. Documenting before the action is completed can lead to errors and is not considered a safe practice, therefore it cannot be the priority.

Choice A rationale

Ranolazine (Ranexa) is an antianginal agent that works by inhibiting the late sodium current in cardiac myocytes. This inhibition leads to a reduction in intracellular calcium overload, improving myocardial relaxation and reducing ventricular wall tension. Unlike many other antianginal drugs, ranolazine does not significantly affect heart rate or blood pressure, making it useful in patients who cannot tolerate the hemodynamic effects of other agents.

Choice B rationale

Ranolazine is not a first-line therapy for angina. It is typically used as a second-line treatment in patients who have not achieved adequate symptom control with beta-blockers, calcium channel blockers, or nitrates. It is often prescribed in combination with other antianginal drugs.

Choice C rationale

Ranolazine is an oral medication available in an extended-release tablet formulation. It is not administered intravenously. The patient takes this medication by mouth, usually twice daily, for the long-term management of chronic angina.

Choice D rationale

Ranexa is metabolized by the liver, specifically via the cytochrome P450 3A (CYP3A) enzyme pathway. Therefore, it is contraindicated or requires significant dose adjustment in patients with moderate to severe hepatic impairment due to the risk of increased plasma concentrations and toxicity.